|
|
Article: Regado's Series B Raises $20M For Blood Thinners.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
With its lead compound in Phase I trials, Duke University spin-out Regado Biosciences Inc. raised $20 million in a Series B financing to boost its work in antidote-controlled anti-thrombotics.
The company has enough cash to operate "into the fourth quarter of 2007," said Douglas Gooding, president of Research Triangle Park, N.C.-based Regado.
The company's approach allows for the rational design of drug-antidote pairs against any target accessible to the bloodstream, with the drug consisting of a modified RNA-based aptamer and the antidote made up of an oligonucleotide complementary to it.
"The technology was in ...